Bourlon Maria T, Urbina-Ramirez Shaddai, Verduzco-Aguirre Haydee C, Mora-Pineda Mauricio, Velazquez Hugo E, Leon-Rodriguez Eucario, Atisha-Fregoso Yemil, De Anda-Gonzalez María G
Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
Universidad Panamericana, Escuela de Medicina, Mexico City, Mexico.
Front Oncol. 2024 Apr 19;14:1334845. doi: 10.3389/fonc.2024.1334845. eCollection 2024.
Patients with adverse pathological features (APF) at radical prostatectomy (RP) for prostate cancer (PC) are candidates for adjuvant treatment. Clinicians lack reliable markers to predict these APF preoperatively. Protein tyrosine phosphatase 1B (PTP-1B) is involved in migration and invasion of PC, and its expression could predict presence of APF. Our aim was to compare PTP-1B expression in patients with and without APF, and to explore PTP-1B expression as an independent prognostic factor.
Tissue microarrays (TMAs) were constructed using RP archival specimens for immunohistochemical staining of PTP-1B; expression was reported with a standardized score (0-9). We compared median PTP-1B score between cases with and without APF. We constructed two logistic regression models, one to identify the independence of PTP-1B score from biologically associated variables (metformin use and type 2 diabetes mellitus [T2DM]) and the second to seek independence of known risk factors (Gleason score and prostate specific antigen [PSA]).
A total of 73 specimens were suitable for TMA construction. Forty-four (60%) patients had APF. The median PTP-1B score was higher in those with APF: 8 (5-9) vs 5 (3-8) (p=0.026). In the logistic regression model including T2DM and metformin use, the PTP-1B score maintained statistical significance (OR 1.21, 95% CI 1.01-1.45, p=0.037). In the model including PSA and Gleason score; the PTP-1B score showed no independence (OR 1.68, 95% CI 0.97-1.41, p=0.11). The area under the curve to predict APF for the PTP-1B score was 0.65 (95% CI 0.52-0.78, p=0.03), for PSA+Gleason 0.71 (95% CI 0.59-0.82, p=0.03), and for PSA+Gleason+PTP-1B score 0.73 (95% CI 0.61-0.84, p=0.001).
Patients with APF after RP have a higher expression of PTP-1B than those without APF, even after adjusting for T2DM and metformin exposure. PTP-1B has a good accuracy for predicting APF but does not add to known prognostic factors.
接受前列腺癌根治术（RP）的患者若具有不良病理特征（APF），则为辅助治疗的候选对象。临床医生缺乏可靠的术前预测这些APF的标志物。蛋白酪氨酸磷酸酶1B（PTP - 1B）参与前列腺癌的迁移和侵袭，其表达可预测APF的存在。我们的目的是比较有和没有APF的患者中PTP - 1B的表达情况，并探讨PTP - 1B表达作为独立预后因素的情况。
使用RP存档标本构建组织微阵列（TMA），用于PTP - 1B的免疫组织化学染色；表达情况用标准化评分（0 - 9）报告。我们比较了有和没有APF的病例之间的PTP - 1B评分中位数。我们构建了两个逻辑回归模型，一个用于确定PTP - 1B评分相对于生物学相关变量（二甲双胍使用情况和2型糖尿病[T2DM]）的独立性，另一个用于探寻已知风险因素（Gleason评分和前列腺特异性抗原[PSA]）的独立性。
共有73个标本适合构建TMA。44名（60%）患者具有APF。有APF的患者中PTP - 1B评分中位数更高：8（5 - 9）对比5（3 - 8）（p = 0.026）。在包含T2DM和二甲双胍使用情况的逻辑回归模型中，PTP - 1B评分保持统计学显著性（OR 1.21，95% CI 1.01 - 1.45，p = 0.037）。在包含PSA和Gleason评分的模型中，PTP - 1B评分未显示出独立性（OR 1.68，95% CI 0.97 - 1.41，p = 0.11）。PTP - 1B评分预测APF的曲线下面积为0.65（95% CI 0.52 - 0.78，p = 0.03），PSA + Gleason为0.71（95% CI 0.59 - 0.82，p = 0.03），PSA + Gleason + PTP - 1B评分为0.73（95% CI 0.61 - 0.84，p = 0.001）。
RP术后有APF的患者PTP - 1B表达高于没有APF的患者，即使在调整T2DM和二甲双胍暴露情况后也是如此。PTP - 1B在预测APF方面具有良好的准确性，但并未增加已知的预后因素。
